-
09:53:22 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

RFL Stock News

08/03/22 8:00 AM
NYSE : RFL
clinical triallow float
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial for CPI-613® (Devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the successful completion of a Phase 1b clinical trial of CPI-613 ®
RHEA-AI
very positive
06/27/22 8:00 AM
NYSE : RFL
conferencesclinical triallow float
Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that data on its lead compound CPI-613 ® (devimistat) in combination
RHEA-AI
neutral
06/01/22 8:00 AM
NYSE : RFL
conferenceslow float
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the Company and its partners will present three abstracts at the
RHEA-AI
neutral